The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


CGB by the numbers
More From The Market Online

Effective as an IV drug, a gel, and now an inhaler – Recce’s R327 can’t stop winning

Recce flagship antibacertial and anti-infective drug R327 has in a model that shows the drug could…
In vitro fertilisation

Monash IVF soars to 85cps as company rejects takeover offer despite -33% YTD returns

Monash IVF Group has soared +40% on Monday morning as the company rejected a non-binding takeover…
Prostate cancer examination discussion concept

Orthocell pops on nerve healing successes in prostate surgery patients

Orthocell has seen its share price jump on Thursday as the company unveils its latest early-stage…
Biotech chart concept

AFT Pharmaceuticals jumps +10% on $115M interim FY26 record revenue

AFT Pharmaceuticals has seen its price jump +10% just shy of $3/sh on Thursday morning as…